Abstract. Cisplatin is a common chemotherapeutic agent against ovarian cancer; however, drug resistance is a major limiting factor for its use in clinical treatment. The underlying mechanisms of cisplatin resistance in ovarian cancer have not yet been fully elucidated. Thus, this study aimed to elucidate some of the mechanisms responsible for resistance to cisplatin in ovarian cancer. The results demonstrated that the cisplatin-resistant human ovarian cancer cell lines, SKOV3/DDP and A2780/DDP, exhibited higher autophagy levels than the control ovarian cancer cell lines, SKOV3 and A2780. Moreover, autophagy inhibition by 3-methyladenine or shRNA against autophagy-related gene (ATG)5 potentiated the cytotoxicity induced by cisplatin, whereas autophagy induction by rapamycin (Rapa) increased cell survival. Exposure to cisplatin induced an upregulation in the expression of thioredoxin-related protein of 14 kDa (TRP14). Furthermore, TRP14 knockdown or overexpression decreased or increased the autophagy response and cisplatin resistance, and this effect was reversed by treatment with Rapa or ATG5 knockdown. The findings of this study also suggested that TRP14 induced autophagy and chemoresistance via the 5'AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR)/p70S6K signaling pathway. Importantly, the data from a tissue array revealed a positive association between TRP14 and Beclin1 in human ovarian cancer and marginal tissues. These findings have identified, for the first time, to the best of our knowledge, that TRP14 induces autophagy and consequently cisplatin resistance in ovarian cancer cells via the AMPK/mTOR/p70S6K signaling pathway. This in turn renders TRP14 as a potential predictor or target in ovarian cancer therapy.
Introduction
Ovarian cancer is the most lethal gynecological malignancy and is the fifth leading cause of cancer-related mortality among women in developing countries (1) . Patients with ovarian cancer are treated with surgical debunking, followed by chemotherapy with a platinum-based drug or paclitaxel (2) . In addition, cisplatin (also known as DDP) is recommended as a common chemotherapeutic agent. As patients eventually become resistant to cytotoxic agents, the overall five-year survival rate is only 44% (3) (4) (5) . Thus, chemoresistance is one of the main causes limiting the effectiveness of chemotherapy (6) .
There is an increasing evidence regarding the association of autophagy and chemoresistance (7) . Autophagy is often known as type II programmed cell death, and is an evolutionarily conserved catabolic process that is responsible for the degradation and recycling of long-lived or aggregated proteins, and excess or defective organelles. Autophagy is induced by a group of autophagy-related (ATG) genes and activates the conversion of cytosolic microtubule-associated protein light chain 3A (LC3A) into LC3B (8, 9) . Autophagy is generally low under basal conditions, while altered autophagic activity has been observed under stress conditions, such as starvation (10) , diverse diseases (11) , irradiation (12, 13) and chemotherapy (14) . Although several studies have demonstrated that various anti-tumor agents induce autophagic cell death in cancer cells (15) (16) (17) , there is compelling evidence to indicate that autophagy contributes to chemoresistance in various types of cancer (18, 19) . It has recently been reported that miR-181a suppresses autophagy and sensitizes gastric cancer cells to cisplatin (20) and also that the suppression of autophagy enhances the efficacy of sunitinib in clear cell ovarian carcinoma (21) . Autophagy has also been shown to contribute to taxol resistance in human colorectal cancer cells (22) .
TRP14 promotes resistance to cisplatin by inducing autophagy in ovarian cancer
Thioredoxin-related protein of 14 kDa (TRP14) is a novel disulfide reductase that belongs to the thioredoxin (TXN) family and was discovered in 2004 (23) . It is also known as thioredoxin domain containing 17 (TXNDC17) and thioredoxin-like 5 (TXNL5) (24) . TRP14 is a TrxR1-dependent reductase that can effectively reduce both S-nitrosothiol and L-cystine levels. The biological function of TRP14 remains unclear however. Previous studies have demonstrated the role of TRP14 in autophagy in mediating taxol resistance by stimulating autophagy in colorectal and ovarian cancer cells (22, 25) . Thus, we hypothesized that there may be an association among TRP14, autophagy and cisplatin resistance in ovarian cancer.
Although there is increasing interest in the modulation of autophagy for cancer therapy, the role of TRP14 in autophagy and cisplatin resistance in ovarian cancer cell lines remains unknown, at least to the best of our knowledge. Hence, in this study, we evaluated the level and effect of autophagy and the function of TRP14 in cisplatin-resistant ovarian cancer cell lines. The findings of this study demonstrate that TRP14 plays a key role in cisplatin resistance through the induction of autophagy. Thus, TRP14 may prove to be a potential predictor or target in ovarian cancer therapy.
Materials and methods
Cell lines, reagents and antibodies. The human ovarian cancer cell lines, A2780 and SKOV3, were obtained from the European Collection of Authenticated Cell Cultures (93112519, ECACC) and the American Type Culture Collection (HTB-77, ATCC), respectively and maintained in RPMI-1640 (10-040-CVR, Corning, Inc.) and McCoy 5A medium (16600-108, Gibco; Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS) at 37˚C in 5% CO 2 . The cisplatin-resistant cells, SKOV3/DDP and A2780/DDP, were established by exposing the cells to gradually increasing concentrations (from 0 to 25 µg/ml) of cisplatin for 6 months (data not shown). Cisplatin was purchased from Hansoh Pharmaceutical Co., Ltd. 3-Methyladenine (3-MA), rapamycin (Rapa), compound C and monodansylcadaverine (MDC) were purchased from Sigma-Aldrich. The primary antibody to TRP14 (ab121725/dilution, 1:500) was purchased from Abcam. The primary antibodies for ATG5 (#12994/dilution, 1:1,000), Beclin1 (#3495/dilution, 1:1,000), LC3B (#3868/dilution, 1:1,000), p-5' AMP-activated protein kinase (AMPK; #2537/dilution, 1:1,000), p-mammalian target of rapamycin (mTOR; #5536/dilution, 1:1,000), p-p70S6K (#9204/dilution, 1:1,000), AMPK (#5832/dilution, 1:1,000), mTOR (#2983/dilution, 1:1,000) and p70S6K (#2708 /dilution, 1:1,000) were obtained from Cell Signaling Technology Inc. The antibody for GAPDH (sc-47724) was purchased from Santa Cruz Biotechnology.
Cell viability assay. Cells were plated in triplicate in 96-well plates overnight and then were treated with or without 200 nM Rapa for 24 h or treated with 4 µM compound C for 12 h. After 12 h, the cells were treated with various concentrations of cisplatin (from 0 to 16 µg/ml) for 24 h. Cell viability was measured using a Cell Counting kit-8 (CCK-8, Dojindo Molecular Technologies, Inc.) assay according to the manufacturer's instructions (25) . Cell viability was calculated according to the following equation: Cell viability=OD value of experimental group/OD value of control group x100%.
Western blot analysis. Cells were harvested and washed with phosphate-buffered saline (PBS). The proteins were extracted, and western blot analysis was performed as previously described (26) . Briefly, the cells were dissolved (for 30 min) in lysis buffer containing 1% PMSF in RIPA buffer (Thermo Fisher Scientific) and quantified using the BCA Protein Assay (Thermo Fisher Scientific). Proteins (30 µg) were resolved on 12% SDS-PAGE, transferred onto polyvinylidenedifluoride transfer membranes (PVDF) and blocked with 5% non-fat dry milk in TBST for 1 h at room temperature. The membranes were incubated with the indicated antibodies overnight at 4˚C, followed by the incubation with the corresponding secondary antibodies (anti-rabbit #7074 and anti-mouse #7076/dilution, 1:5,000, Cell Signaling Technology Inc.) conjugated with horseradish peroxidase-conjugated (HRP) for 1 h at room temperature. The bands were detected with an EZ-ECL kit (BI Biological Industries, 20-500-120) in the MicroChemi bio-imaging system (DNR). ImageJ was used for densitometry (Image J 1.46r, National Institutes of Health).
Plasmids and shRNA transfection. The pcDNA3.1(C)-TRP14 plasmid was constructed based on the following description. The fragment (182 to 553) of TRP14 mRNA was synthesized and inserted into the pcDNA3.1(C) vector (Invitrogen; Thermo Fisher Scientific, #V790-20). The pcDNA3.1(C) vector was considered as the mock control. DNA oligonucleotides carrying shRNA (Invitrogen-Life Technology; Thermo Fisher Scientific) were constructed into the pLKO.1 plasmid (Addgene Plasmid #8453). The packaging plasmid psPAX2 (Addgene Plasmid #12260) and envelop plasmid pMD2.G (Addgene Plasmid #12259) were transfected into 293T cells (from Cell Bank of the Chinese Academy of Sciences)with recombinant plasmids using LipofectamineTM2000 (Invitrogen; Thermo Fisher Scientific). The supernatant containing lentiviruses was collected after 36 h. The sequences of the shRNAs were as follows, TRP14 shRNA#1, GTG CCT ACA CTA CTT AAG T; TRP14 shRNA#2, ACC TAA CCT CAC CAC TGA A; ATG5 shRNA#1, GCT ACT CTG GAT GGG ATTG; ATG5 shRNA#2, ATT GGC TCA ATT CCA TGA A; and control shRNA, CAC ACC GTT TCG TGG CTT T. Cells were grown till 80% confluence prior to transfection. Transfected cells were grown for 2 weeks in the presence of puromycin (0.2 µg/ml) before they were used for subsequent experimentation. RFP-LC3 analysis. The cells were then transfected with a GFP-RFP-LC3 plasmid (Addgene Plasmid #84573) using LipofectamineTM2000 and 24 h later, the cells were transferred onto coverslips. The cells were washed with PBS and fixed with 4% PFA in PBS for 30 min at room temperature. The fixed cells were washed twice with PBS and then permeabilized with 0.5% Triton X-100 in PBS for 2 min on ice. Images were obtained under an Olympus BX50 fluorescence microscope (Olympus).
Electron microscopy analysis. Following treatment with 200 nM Rapa for 12 h, and the knockdown or overexpression of TRP14, the cells were harvested and washed with PBS. The samples were processed and detected as previously described (27) . Briefly, the cells were exposed to 10 nM paclitaxel for 24 h and fixed with 2.5% glutaraldehyde solution (Sigma-Aldrich, G5882) overnight, then post-fixed with 1% OsO4 and dehydrated standard in graded ethanol, embedded in 812 resin (Ted Pella, 18109). Thin sections were sliced and stained with 2% uranyl acetate, and then examined with a JEM-100CX transmission electron microscope (Jeol). A control group without drugs was also set. All cells were cultured at 37˚C and 5% CO 2 for 24 h. Subsequenlty, 20 µl of MTT (5 mg/ml) solution were added to each well and the cells were cultured for an additional 4 h. Supernatants were discarded after termination of the culture and 150 µl of dimethyl sulphoxide (DMSO) were added to each well. The plates were shaken for 10 min and a microplate reader was used to measure the optical density (OD) value at a wavelength of 570 nm to calculate cell survival rate. The following equation was used to calculate the cell survival rate: Cell survival rate=(the OD value in each experiment well/the OD value in the control well) x100%. The 50% of inhibition concentration (IC50) of drug was measured by chartography. The drug resistance index (DRI)=the IC50 of drug-resistant cells/the IC50 of parent cell line. MTT experiments were repeated 3 times on time points(every 24 h).
Drug resistance index (DRI) assay.
Immunohistochemistry. The clinical ovarian cancer and marginal tissue microarray (BC11115b from US Biomax) was analyzed based on the following description. After dewaxing and hydration, the tissue microarray slides were boiled in sodium citrate buffer for 10 min for antigen recovery, and Statistical analysis. All analyses were repeated at least 3 times. Data are expressed as means ± SD. Statistical analysis of the data was performed using a Student's t-test and two-tailed distribution. The Kruskal-Wallis test was used for multiple comparisons and then Mann Whitney U test as well as Bonferroni's correction were applied as post hoc tests to determine the cell viability difference among the different groups.
Results

Autophagy is induced in cisplatin-resistant human ovarian cancer cell lines.
To identify the chemoresistance of cisplatin-resistant human ovarian cancer cell lines, the cisplatin-resistant human ovarian cancer cell lines, SKOV3/DDP, A2780/DDP, and the control cell lines, SKOV3/A2780, were treated with various concentrations of cisplatin for 24 h. CCK-8 and drug resistance index (DRI) assay were then performed to measure the cell viability and drug sensitivity in the different cells (Fig. 1A and B) . The results revealed that the survival of both the SKOV3 and SKOV3/DDP cells decreased in a dose-dependent manner. However, the SKOV3/DDP cells were more resistant to cisplatin, as compared with the SKOV3 cells (P<0.05). Similar results were clearly observed in the A2780 and A2780/DDP cells (Fig. 1A) . Moreover, our data suggested that the DRI was much higher in the SKOV3/DDP compared to A2780/DDP cells, indicating that the SKOV3/DDP cells were more resistant than the A2780/DDP cells. Recently, it has been demonstrated that autophagy is associated with drug resistance (25) . Thus, the contribution of autophagy to cisplatin resistance was determined in this study. As shown in Fig 1C, the levels of LC3, Beclin1 and ATG5, which are the characteristics of autophagy (15, 28) , were elevated in the SKOV3/DDP and A2780/DDP cells when compared with the SKOV3 and A2780 cells, respectively (Rapa treatment was used as a positive control). Furthermore, the acidic vesicular organelles (AVOs) were examined by MDC staining. A greater number of the SKOV3/DDP and A2780/DDP cells were MDC-positive cells compared with their sensitive counterparts, the SKOV3 and A2780 cells (Fig. 1D) . According to these observations, the numbers of GFP-RFP-LC3-positive puncta were significantly increased in the cisplatin-resistant ovarian cancer cells (Fig. 1E ). More importantly, these results were validated using transmission electron microscopy (Fig. 1F) . These data clearly indicated that cisplatin-resistant human ovarian cancer cell lines displayed an enhanced autophagy status when compared with the control cell lines, SKOV3 and A2780.
Autophagy is required for cisplatin resistance in human ovarian cancer cells. To elucidate the role of autophagy in the resistance of human ovarian cancer cell lines to cisplatin, the autophagy inhibitor, 3-MA was used (29) . As shown in Fig. 2A , the levels of LC3, Beclin1 and ATG5 were significantly decreased in the SKOV3/DDP and A2780/DDP cells following treatment with 5 nM 3-MA for 24 h. As expected, treatment with 3-MA significantly decreased the viability of the SKOV3/DDP and A2780/DDP cells (Fig. 2B) . To assess the role of autophagy in cisplatin resistance, autophagy was inhibited through genetic methods (silencing of ATG5) in the SKOV3/DDP and A2780/DDP cells. Following the silencing of ATG5, the viability of the SKOV3/DDP and A2780/DDP cells exhibited a significant attenuation (Fig. 2C and D) , indicating that the cytotoxic effects of cisplatin were enhanced by ATG5 knockdown. Since the DRI was greater in the SKOV3 cells than in the A2780 cells (Fig. 1B) , Rapa (200 nM) was used to induce autophagy in the SKOV3 cells (Fig. 2E-H) . The results revealed that the expression levels of LC3, Beclin1 and ATG were markedly upregulated by Rapa in the SKOV3 cells (Fig. 2E) . Consistent with the above-mentioned results, MDC staining, GFP-RFP-LC3 transfection and transmission electron microscopy analysis confirmed that cisplatin triggered autophagy in the SKOV3 cells (Fig. 2F-H) , as evidence by the increased number of GFP-RFP-LC3-positive puncta, MDC-positive cells, and autolysosome vesicles. Moreover, cisplatin exhibited significant cytotoxicity in the SKOV3 cells and A2780 cells in a dose-dependent manner (Fig. 2I) . These findings suggested that cisplatin induced autophagic cell death in the SKOV3 cells. Similar results were observed in the A2780 cells (data not shown). Taken together, these results clearly demonstrated that autophagy modulated cisplatin resistance in human ovarian cancer cells.
TRP14 knockdown suppresses autophagy-induced cisplatin resistance.
Previous studies have reported that TRP14 promotes taxol resistance by inducing autophagy (22, 25) . Thus, we hypothesized that TRP14 may also participate in autophagy-induced cisplatin resistance in human ovarian cancer cells. The results revealed that the protein expression of TRP14 was significantly increased in the SKOV3/DDP and A2780/DDP cells when compared with the SKOV3 and A2780 cells, respectively (Fig. 3A) . To confirm the function of TRP14 in autophagy-regulated cisplatin resistance, TRP14 was knocked down using shRNA against different regions of TRP14 mRNA in the SKOV3/DDP and A2780/DDP cells (Fig. 3B) . As shown in Fig. 3C -F, TRP14 knockdown significantly inhibited autophagy in the SKOV3/DDP and A2780/DDP cells, as determined by western blot analysis, MDC staining, transmission electron microscopy observation and GFP-RFP-LC3 transfection. In addition, TRP14 knockdown significantly increased the sensitivity of the SKOV3/DDP and A2780/DDP cells to cisplatin ( Fig. 3G  and H) . To verify the role of autophagy in cisplatin resistance induced by TRP14 knockdown, Rapa was used. As shown in Fig. 3G and H, Rapa promoted resistance to cisplatin when TRP14 was knocked down. Taken together, these data clearly indicated that TRP14 knockdown suppressed autophagy-induced cisplatin resistance in the SKOV3/DDP and A2780/DDP cells.
TRP14 overexpression promotes autophagy and cisplatin resistance in human ovarian cancer cells.
To further confirm the role of TRP14, autophagy and cisplatin resistance in human ovarian cancer cells, TRP14 was overexpressed in the SKOV3 and A2780 cells (Fig. 4A) . The results revealed that the levels of the autophagy marker proteins, the number of RFP-positive cells and the number of autophagosomes were significantly increased by TRP14 overexpression (Fig. 4B-D) . These findings indicated that TRP14 induced autophagy in human ovarian cancer cells. Moreover, TRP14 overexpression exerted protective effects on the ovarian cancer cells against cisplatin (Fig. 4E and F) . However, cytoprotection due to TRP14 overexpression was partly reversed by ATG5 knockdown (Fig. 4E and F) . Taken together, these results suggested that TRP14 activated autophagy and induced cisplatin resistance, at least partially through the participation of ATG5. TRP14 induces autophagy and chemoresistence via the AMPK/mTOR/p70S6K signaling pathway. Subsequenlty, the AMPK and mTOR signaling pathways were investigated in the cisplatin-resistant human ovarian cancer cells. According to a previous study, the AMPK and mTOR signaling pathways regulate autophagy (30) . Western blot analysis was thus performed to elucidate the phosphorylation levels of AMPK, mTOR and p70S6K in the SKOV3/DDP and A2780/DDP cells. As shown in Fig. 5A , the phosphorylation levels of AMPK were increased in the SKOV3/DDP and A2780/DDP cells, whereas the phosphorylation levels of mTOR and p70S6K were decreased. These results indicated the involvement of autophagy in cisplatin-resistant human ovarian cancer cells and the role of the AMPK/mTOR/p70S6K signaling pathway. To further confirm the involvement of AMPK, mTOR and p70S6K signaling in cisplatin-resistant human ovarian cancer cells and the induction of autophagy, the AMPK inhibitor, compound C, was employed. Compound C partially, but significantly reversed cisplatin-resistance in the SKOV3/DDP and A2780/DDP cells ( Fig. 5D and E) . These results clearly indicated that cisplatin resistance was mediated by AMPK, mTOR and p70S6K signaling in ovarian cancer cells. Our results also revealed that TRP14 acts as an autophagy and chemoresistence promoter (Figs. 3 and 4) . Thus, we investigated the association of the TRP14 in the AMPK/mTOR/p70S6K signaling pathway. TRP14 was overexpressed in the SKOV3 and A2780 cells and detected the phosphorylation levels of AMPK, mTOR and p70S6K. These results suggested that TRP14 markedly activated the AMPK/mTOR/p70S6K signaling pathway (Fig. 5B) . To further validate the regulation of the AMPK/mTOR/p70S6K signaling pathway by TRP14, TRP14 shRNA2 was used in SKOV3/DDP and A2780/DDP cells. As expected, the phosphorylation of AMPK exhibited a decrease, whereas the phosphorylation of mTOR and p70S6K exhibited an increase (Fig. 5C ). These findings revealed that TRP14 induced autophagy and chemoresistence via the AMPK/mTOR/p70S6K signaling pathway.
Positive association of TRP14 and Beclin1 proteins in ovarian cancer tissues. The above-mentioned results supported the conclusion that TRP14 promotes paclitaxel resistance by inducing autophagy via the AMPK/mTOR/p70S6K signaling pathway in ovarian cancer. To further determine whether there was an association between TRP14 and Beclin1, we used a tissue array of human ovarian cancer. The tissue array was composed of 5 cases of clear cell carcinoma, 62 cases of serous adenocarcinoma, 12 cases of mucinous adenocarcinoma, 1 case of endometrioid carcinoma, 10 cases of lymph node metastatic adenocarcinoma and 10 cases of marginal tissue. The representative strains from the specimens are shown in Fig. 6A and B. The results revealed that along with the increment in the TRP14 protein levels, the expression of Beclin1 was markedly increased (Fig. 6C) . Collectively, these results strongly suggested that the expression of TRP14 and Beclin1 proteins are positively associated in ovarian cancer tissues.
Discussion
Cisplatin is known as the 'penicillin of cancer', and is widely used in the treatment of various types of cancer, including ovarian cancer. However, cisplatin-based resistance is a major obstacle in chemotherapy (31) . The mechanisms associated with cisplatin resistance in ovarian cancer remain unclear. Hence, in this study, we aimed to elucidate the possible underlying mechanisms of the effects of cisplatin on ovarian cancer cells using sensitive SKOV3 (A2780) and resistant SKOV3/DDP (A2780/DDP) cells as the ideal pairs of cell models. Autophagy plays a dual role in cancer. According to some early reports, autophagy was considered to be a tumor suppressor (32) , while others consider that cancer cells rely on autophagy (33) . More importantly, there is increasing evidence to indicate that the activation of autophagy is involved in the chemoresistance of cancer cells, while the inhibition of autophagy significantly improves the effects of therapy (34) (35) (36) . In this study, the levels of LC3, Beclin1 and ATG5 were compared in both ovarian cancer cells. Accordingly, the protein expression levels of LC3, Beclin1 and ATG5 were high in the cisplatin-resistant cells, while they were low in the sensitive cells (Fig. 1C) . Consistent with these results, MDC staining, GFP-RFP-LC3 transfection and transmission electron microscopy analysis confirmed that cisplatin-resistant ovarian cancer cells triggered autophagy (Fig. 1) . In line with previous findings (15) , this study revealed that the inhibition of autophagy by treatment with 3-MA or the silencing of ATG5 augmented cisplatin cytotoxicity (Fig. 2) , suggesting the importance of autophagy in the pharmacological modulation of ovarian cancer cells in response to cisplatin. Moreover, the induction of autophagy by Rapa increased the survival of the SKOV3 and A2780 cells (Fig. 2E-I ). These data indicated that autophagic cell death was a possible mechanism for cisplatin-induced cytotoxicity and changes in autophagy in the sensitivity to chemotherapy.
There is increasing evidence to indicate that TRP14 promotes taxol resistance by inducing autophagy (25) . To confirm whether TRP14 also participates in autophagy-mediated cisplatin resistance in ovarian cancer cells, the expression of TRP14 was initially detected. The protein levels of TRP14 were substantially increased in SKOV3/DDP and A2780/DDP cells (Fig. 3A) . To illustrate the role of TRP14 in the resistance of ovarian cancer, TRP14 was knocked down using shRNA (Fig. 3B) . The results revealed that cisplatin sensitivity was increased when TRP14 was substantially suppressed by shRNA (Fig. 3D-H) . By contrast, autophagy was induced and cisplatin sensitivity was attenuated when TRP14 was overexpressed (Fig. 4) . Taken together, these results clearly demonstrated that TRP14 induced cisplatin resistance, at least partly by inducing autophagy.
Based on the clinical data of the connection between autophagy and the AMPK/mTOR signaling pathway, the signaling pathway in resistant human ovarian cancer cells was evaluated. As shown in Fig. 5 , the overexpression of TRP14 in the SKOV3 and A2780 cells activated the AMPK signal, and inhibited the mTOR and p70S6K signaling pathways. Based on these data, TRP14 may modulate these molecules, and it may be located upstream of these molecules. Moreover, the data from a tissue array (Fig. 6) suggested that the protein expression of TRP14 and Beclin1 exhibited a positive association, supporting the view that TRP14 activated autophagy in ovarian cancer cells.
In conclusion, this study, identified that TRP14 mediated cisplatin resistance through the induction of autophagy in human ovarian cancer cells via the AMPK/mTOR/p70S6K signaling pathway. Moreover, TRP14 and Beclin1 were positively associated in human ovarian cancer and marginal tissues. Although the detailed underlying mechanisms require further investigation, TRP14 may be regarded as a promising therapeutic target for managing cisplatin resistance in human ovarian cancer.
